Bio-Path (BPTH) Earning Somewhat Favorable Press Coverage, Study Shows

News stories about Bio-Path (NASDAQ:BPTH) have been trending somewhat positive on Tuesday, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Path earned a news impact score of 0.11 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.2320507080849 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Separately, ValuEngine raised shares of Bio-Path from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

NASDAQ:BPTH traded up $0.03 during trading hours on Tuesday, hitting $1.82. The stock had a trading volume of 51,915 shares, compared to its average volume of 289,477. Bio-Path has a 1-year low of $1.53 and a 1-year high of $7.30. The company has a market capitalization of $21.21, a price-to-earnings ratio of -2.28 and a beta of 2.72.

WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3385674/bio-path-bpth-earning-somewhat-favorable-press-coverage-study-shows.html.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Insider Buying and Selling by Quarter for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Markel Co.  Vice Chairman Steven A. Markel Sells 200 Shares
Markel Co. Vice Chairman Steven A. Markel Sells 200 Shares
Bottomline Technologies, Inc.  Director Peter Gibson Purchases 4,000 Shares
Bottomline Technologies, Inc. Director Peter Gibson Purchases 4,000 Shares
Old Dominion Freight Line  Director Leo H. Suggs Sells 800 Shares of Stock
Old Dominion Freight Line Director Leo H. Suggs Sells 800 Shares of Stock
Cara Therapeutics  SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Cara Therapeutics SVP Frederique Ph.D. Menzaghi Sells 9,000 Shares
Analysts Set Nexeo Solutions  Price Target at $11.17
Analysts Set Nexeo Solutions Price Target at $11.17
Hologic, Inc.  Given Average Recommendation of “Hold” by Analysts
Hologic, Inc. Given Average Recommendation of “Hold” by Analysts


© 2006-2018 Ticker Report. Google+.